RFK Jr. Overhauls Federal Autism Panel, Sparking Medical Community Backlash 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
NASA Cuts Boeing Starliner Missions as SpaceX Pulls Ahead 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
Asian Stocks Slip as Tech Rout Deepens, Japan Steadies Ahead of Election 
Neuren Pharmaceuticals Surges on U.S. Patent Win for Rare Disorder Drug 
Trump Lifts 25% Tariff on Indian Goods in Strategic U.S.–India Trade and Energy Deal 
SpaceX Starship Explodes in Texas During Test, Citing Nitrogen Tank Failure 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Tokyo Medical and Dental University and the National Center of Neurology and Psychiatry are planning to develop tailored drugs for patients with genetic disorders to find treatment for extremely rare diseases.
The two Japanese medical institutions will search for rare diseases that have the potential to be treated by nucleic acid drugs from a database of around 2,250 patients.
Nucleic acid drugs are an emerging class of therapeutics,
The development will be carried out based on technology that targets the expression of disease-causing proteins in the mutant gene.
Due to the price and challenges with financial viability, pharmaceutical companies are hesitant to develop medications for exceedingly rare disorders.
According to Takanori Yokota, a professor of neurology and neurological science at Tokyo Medical and Dental University, they hope to make effective patient-tailored nucleic acid drugs and find as many people who can be treated.
The Initiative on Rare and Undiagnosed Diseases, a study that examines the DNA of people whose diseases cannot be detected or for which there is no known cure, will be used to pick participants from among the patients registered in it.
The project catalogs approximately 1,700 linked gene sequences and covers a wide spectrum of illnesses, such as neurological, cardiac, and metabolic problems.
In Japan, only one or two family lines are affected by about 70% of the diseases, and many do not have any reliable treatments.
In addition to the causative gene, factors such as age, the severity of symptoms, and the speed at which the disease is progressing will be taken into account when choosing candidate patients.
